---
title: "Clinical features and hospital management of snakebite in Northern Uganda: multi-facility review"
id: "plos-one-15-clinical-features-first-aid-practices-and-hospital-management-of-snakebites-in"
canonical_url: "https://medichelpline.com/clinical-feed/plos-one-15-clinical-features-first-aid-practices-and-hospital-management-of-snakebites-in"
content_type: "clinical_feed_article"
specialty: "General"
source_name: "PLOS ONE (Medicine)"
source_url: "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0363220"
published_at: "2026-11-19T14:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Clinical features and hospital management of snakebite in Northern Uganda: multi-facility review
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/plos-one-15-clinical-features-first-aid-practices-and-hospital-management-of-snakebites-in
- **Specialty:** [General](https://medichelpline.com/clinical-feed/general.md)
- **Primary Source:** PLOS ONE (Medicine)
- **Source URL:** [Original Journal Publication](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0363220)
- **Published At:** 2026-11-19T14:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- Investigators reviewed 227 facility records of **snakebite** from four purposively selected health facilities in Gulu and Arua districts, covering 2017–2021. - The analysis used a standardised retrospective abstraction tool; descriptive statistics were run in Stata v14 and were complete-case, with medians and IQRs reported for skewed continuous variables. - The cohort was 58.6% female; median age 21 years (IQR 13–38); students/pupils made up 26.6% where occupation was recorded. - Most bites affected the lower limb (85.9%) and clustered in the second and third quarters of the year (59.9%). - Snake species was not documented in 76.2% of records; species-level data were largely missing from routine charts. - No pre-hospital first aid was recorded for 59.1% of patients; when recorded, harmful measures predominated — tourniquets (29.3%) and herbal remedies (8.9%). - Local signs dominated: pain (60.8%), swelling or blisters (68.7%), and fang marks (26.9%). - Features suggesting systemic envenoming appeared in 18.5% of cases; of those, one-third (33.3%) received **antivenom**. - Overall **antivenom** use was 15.0%; supportive therapies were common: intravenous fluids (68.1%), analgesics (64.2%), antibiotics (53.1%). - Coagulation testing was infrequent: **20WBCT** recorded in 17.3% and INR in 12.0% of records. - Outcomes recorded: 93.4% recovered, 3.1% died, 0.9% referred, 2.6% had missing outcome data. - The authors reported critical gaps in species identification, syndromic assessment, coagulation testing, antivenom utilisation, and pre-hospital care, and called for improved training, documentation, surveillance, and community education.
## Clinical Analysis & Structured Key Points
Clinical features, first aid practices, and hospital management of snakebites in Northern Uganda: A multi-facility cross-sectional study | PLOS One Browse Subject Areas ? Click through the PLOS taxonomy to find articles in your field. For more information about PLOS Subject Areas, click here . Article Authors Metrics Comments Media Coverage Reader Comments Figures Figures Abstract Snakebite envenoming is a neglected tropical disease with a disproportionate burden in sub-Saharan Africa, where weak surveillance, limited antivenom availability, and reliance on traditional remedies compound morbidity and mortality. Evidence on how snakebite cases are clinically managed in routine practice in Uganda remains scarce. We conducted a facility-based cross-sectional study with retrospective abstraction of records from four purposively selected health facilities in Gulu and Arua Districts of Northern Uganda. Snakebite case records from outpatient, inpatient, paediatric, and intensive-care service points covering the period 2017–2021 were reviewed using a standardised abstraction tool. Descriptive statistics were computed in Stata version 14, with frequencies and proportions for categorical variables and medians with interquartile ranges (IQR) for continuous variables, both of which were right-skewed. All analyses were complete-case, and the denominator is reported wherever it differs from the full sample. We analysed 227 snakebite case records. Of these, 58.6% were female and the median age was 21 years (IQR 13–38); students or pupils accounted for 26.6% of the 192 records in which occupation was described. Most bites involved the lower limb (85.9%) and occurred in the second and third quarters of the year (59.9%). Snake species was undocumented in 76.2% of records. No pre-hospital first aid was recorded in 59.1% of cases; where first aid was documented it was usually harmful, most often a tourniquet (29.3%) or a herbal remedy (8.9%). The dominant clinical manifestations were pain (60.8%), swelling or blisters at the bite site (68.7%), and fang marks (26.9%). One or more features suggestive of systemic envenoming were documented in 18.5% of cases, of whom 33.3% received antivenom. Overall, only 15.0% of cases received antivenom, while supportive care predominated (intravenous fluids 68.1%, analgesics 64.2%, antibiotics 53.1%). Coagulation testing was rare (20-minute whole blood clotting test 17.3%; INR 12.0%). Overall, 93.4% of patients recovered, 3.1% died, 0.9% were referred to other healthcare facilities, and the rest (2.6%) had missing information on the outcomes. Snakebite management in Northern Uganda is largely symptomatic, with critical gaps in species identification, syndromic assessment, coagulation testing, antivenom utilisation, and pre-hospital first aid practices. Strengthening health-worker training, improving documentation and surveillance, and community education on appropriate first aid are urgently needed to reduce preventable morbidity and mortality. Citation: Wafula ST, Akello T, Mubiru S, Mugambe RK, Isunju JB, Ddamulira JB, et al. (2026) Clinical features, first aid practices, and hospital management of snakebites in Northern Uganda: A multi-facility cross-sectional study. PLoS One 21(11): e0363220. https://doi.org/10.1371/journal.pone.0363220 Editor: Seyed Shahmy, National Science and Technology Commission, SRI LANKA Received: July 27, 2026; Accepted: November 5, 2026; Published: November 19, 2026 Copyright: © 2026 Wafula et al. This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability: The data underlying this study were abstracted from routine clinical records that remain the property of the participating health facilities and were accessed under administrative clearance that does not permit public deposition. De-identified data supporting the findings are available to researchers who meet the criteria for access to confidential data, on request to the Makerere University School of Public Health Higher Degrees, Research and Ethics Committee (MakSPH-HDREC), School of Public Health, Makerere University, P.O. Box 7072, Kampala, Uganda (email: jkaggayi@musph.ac.ug , quoting protocol reference SPH-2021-210. Requests may also be directed to the corresponding author at swafula@musph.ac.ug . Funding: This study was funded by the Royal Society of Tropical Medicine and Hygiene (RSTMH) to STW. The funder had no role in the design and implementation of the study. Competing interests: The authors have declared that no competing interests exist. Introduction Snakebite envenoming is a life-threatening medical emergency caused by the injection of venom through the bite of a venomous snake or, for some species, defensive spitting of venom into the eyes, leading to severe ocular damage [ 1 , 2 ]. Globally, an estimated 4.5–5.4 million people are bitten by snakes annually, of which 1.8–2.7 million develop clinically significant envenoming, resulting in an estimated 81,000–138,000 deaths and roughly three times as many permanent disabilities, including amputations [ 3 , 4 ]. Clinical sequelae can include neurotoxic paralysis with respiratory failure, venom-induced consumptive coagulopathy and haemorrhage, acute kidney injury, and extensive local tissue necrosis that may necessitate limb amputation [ 4 – 6 ]. Recognising the magnitude of the problem, in 2017, the World Health Organization (WHO) reinstated snakebite envenoming on the priority list of neglected tropical diseases and two years later (2019), set a global target of halving snakebite-related mortality and disability by 2030 [ 7 ]. The burden of snakebite is concentrated in low- and middle-income countries (LMICs), where weak health systems, scarce antivenom, geographical inaccessibility of facilities, and the economic vulnerability of rural farming and pastoral communities compound the problem [ 8 – 10 ]. These constraints are not skewed to Africa because in a prospective cohort of 476 snakebite admissions to a tertiary hospital in south-western Nepal, an envenomed patient died without receiving antivenom because stock had run out [ 11 ]; and in an analysis of snakebite deaths reported in Nepali news media between 2010 and 2022, fatality was associated with how remote the bite location was [ 12 ]. Sub-Saharan Africa (SSA) reports an estimated 314,000–435,000 envenomings and 7,300–20,000 deaths annually, which is more than 30% of global snakebite mortality [ 13 , 14 ]. The health-economic toll is heavy in both regions. In SSA, including Uganda, snakebite imposes catastrophic out-of-pocket costs to households and productivity losses on national economies [ 15 , 16 ]. The same pattern is documented in South Asia, where the cost of a single bite measurably erodes household economies in southern Nepal [ 17 ] and drives loss of earnings among rural agricultural populations in Tamil Nadu, India [ 18 ]. Across all these settings, antivenom supply remains a challenge and its price beyond the reach of most affected households. In Uganda, the true incidence of snakebite is poorly characterised because of weak surveillance and incomplete facility documentation [ 8 , 19 ]. A multi-facility survey of 140 health units across six regions in Uganda documented 593 snakebite cases over six months, which indicates a substantial but under-recorded burden [ 9 ]. Population-based estimates suggest an annual incidence of approximately 101 bites per 100,000 people, with the highest rates in Northern Uganda, where tropical climate, agricultural occupations, and a high diversity of medically important snakes converge [ 20 ]. The country’s savannah, wetland, and rainforest ecosystems harbour several clinically important snake species, including the black mamba ( Dendroaspis polylepis ), puff adder ( Bitis arietans ), and various cobras ( Naja spp.) [ 7 ]. Hospital series from Uganda describe the resulting envenoming as predominantly neurotoxic, cytotoxic, or haemotoxic [ 10 , 19 ]. Effective hospital management of snakebite largely depends on rapid syndromic assessment, judicious use of the 20-minute whole-blood clotting test (20WBCT) and other coagulation indices, timely administration of polyvalent antivenom in indicated cases, and supportive care for systemic complications [ 7 , 19 ]. However, knowledge and awareness among healthcare workers and the public remain limited across LMIC settings in both regions; in Bhutan, for example, health workers surveyed on snakes and snakebite management showed substantial gaps in both identification and treatment [ 21 – 23 ]. Additionally, pre-hospital practices such as tourniquet application, incision and suction, and herbal remedies persist despite evidence of harm [ 8 , 24 , 25 ], in part because inadequate first-aid teaching sustains them: a review of textbooks used by non-medical and paramedical students in Nepal found harmful interventions still presented as standard first aid [ 26 ]. Studies from Uganda and neighbouring countries have documented variable adherence to clinical guidelines, suboptimal antivenom utilisation, and frequent over-reliance on antibiotics and supportive care [ 9 , 19 ]. Generating context-specific evidence on how snakebite is actually managed in routine practice is therefore essential to inform clinical guidelines, training, antivenom procurement, and community education. This study, therefore, aimed to describe the demographic and clinical characteristics, pre-hospital first aid practices, in-hospital diagnostic evaluation, treatment, and outcomes of snakebite cases presenting to selected health facilities in Northern Uganda. The findings are intended to inform clinical guidelines, capacity-building for healthcare workers, antivenom supply planning, and public-health interventions aimed at reducing snakebite-related morbidity and mortality in the country. Methods Study design This was a facility-based, cross-sectional study using retrospective abstraction of routine clinical records to characterise snakebite cases and assess the quality of in-hospital management in Northern Uganda. The data abstraction was conducted from 08/05/2022 to 16/05/2022. The study has been reported in accordance with the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) statement for cross-sectional studies [ 27 ]. Study setting The study was conducted in Gulu and Arua Districts, which are recognised as high-burden areas for snakebite envenomation in Northern Uganda [ 10 , 20 ]. The region is predominantly rural, with communities largely engaged in subsistence agriculture, livestock keeping, and fishing, which leads to frequent human–snake interactions. Recent population data from the Uganda Bureau of Statistics indicate substantial populations in both districts and their urban centres, including approximately 384,656 residents in Arua City and 233,271 in Gulu City [ 28 ]. Population growth and settlement expansion into previously undisturbed ecosystems are likely to increase the frequency of human–snake interactions and demand for snakebite care. Gulu and Arua districts in Northern Uganda experience a substantial snakebite burden and require a health system with adequate capacity to prevent, diagnose, and manage snakebite envenomation [ 21 ]. Gulu District, with an estimated population of 443,733, has 65 health facilities comprising 33 government, 15 private, and 17 private-not-for-profit (PNFP) facilities, while Arua District, with an estimated population of approximately 750,000, has 58 health facilities, including 36 government, 17 private, and 5 PNFP facilities [ 21 ]. Both districts are served by Regional Referral Hospitals and several general hospitals, Health Centre IVs, Health Centre IIIs, and Health Centre IIs that provide varying levels of emergency and inpatient care. Four of these facilities; two in Gulu District and two in Arua District were included in the present study. Epidemiological estimates indicate that Gulu and Arua reported annual snakebite incidences of approximately 104 and 73 cases per 100,000 population, respectively, placing them among Uganda’s high-burden districts [ 21 ]. The predominantly rural populations, whose livelihoods depend on crop farming and fishing, coupled with favourable ecological conditions for venomous snakes, contribute to this elevated burden [ 21 ]. Despite the existing health infrastructure, snakebite management remains constrained by inadequate antivenom availability, limited training for healthcare workers, insufficient clinical guidelines, weak referral systems, and shortages of essential medicines and laboratory support, underscoring the need to strengthen health system preparedness and capacity for effective snakebite management in these districts [ 8 ]. Site selection and sampling Gulu and Arua Districts serve as significant health service hubs in Northern Uganda, each housing a Regional Referral Hospital, the highest referral facility in its sub-region. These districts are supported by a network of Health Centre IVs, Health Centre IIIs, Health Centre IIs, and private and non-profit facilities that provide preventive, curative, emergency, and referral services to both local populations and neighbouring districts. These facilities manage medical emergencies, including snakebite envenoming. Given that Northern Uganda has the highest incidence of snakebites in the country, Gulu and Arua are particularly suitable locations for evaluating health system readiness and healthcare workers’ capacity in snakebite management. Four health facilities were purposively selected for this study. We selected these facilities based on the assumption that they possess adequate resources and supplies to effectively handle snakebites, and that they are likely to receive most snakebite cases in the area [ 29 ]. Purposive selection was used because snakebite that reaches the formal health system is managed almost entirely at facilities that admit patients and hold antivenom; lower-level health centres in both districts refer such cases upward. The four sites comprise the Regional Referral Hospitals for the Acholi and West Nile sub-regions together with the largest private-not-for-profit and private hospitals in the two districts and therefore capture the facilities to which severe and referred cases converge. They are not a probability sample of either district. Cases managed at Health Centre II–IV level, at facilities in neighbouring districts, or outside the formal health system are not represented, and the split of cases between Arua (n = 38) and Gulu (n = 189) reflects the completeness and retrievability of records at each site rather than the true district-level distribution of snakebite. The consequences of this design for generalisability are set out in the Limitations section. In Gulu District, the selected facilities were Gulu Regional Referral Hospital and St. Mary’s Hospital Lacor. In Arua District, the selected facilities were Arua Regional Referral Hospital and Rhema Hospital. Gulu Regional Referral Hospital and Arua Regional Referral Hospital are public Regional Referral Hospitals under the Ministry of Health that provide specialised and referral healthcare services to large catchment populations across the Acholi and West Nile sub-regions, respectively, while also serving as teaching and internship centres [ 30 , 31 ]. St. Mary’s Hospital Lacor is a large private-not-for-profit (PNFP) hospital that complements public health services by providing comprehensive secondary and tertiary care to patients from Gulu District and neighbouring districts [ 32 ]. Rhema Hospital is a private hospital that provides general medical, surgical, obstetric, and emergency services, contributing to healthcare delivery in Arua City and the wider West Nile region [ 33 ]. All records with a diagnosis of snakebite captured in the routine registers and clinical files during the period 1 January 2017 to 31 December 2021 were eligible for inclusion. This five-year period was purposively selected to provide an adequate sample of snakebite cases for analysis, capture potential year-to-year and seasonal variations in snakebite occurrence and management, and ensure the use of complete and consistently archived hospital records available at the time of data collection. 2017 as the start year also coincided with WHO recognition of snakebites as a neglected tropical disease (NTD). Records were excluded if the presenting complaint was an animal bite or sting other than snakebite; if the entry duplicated a record already abstracted for the same patient and bite episode; or if the entry carried neither a date of presentation nor any clinical detail, so that a snakebite episode within the study period could not be confirmed. No record was excluded on the basis of age, sex, district of residence, envenoming severity, or treatment outcome. Of 793 register entries screened across the four facilities, 227 were identified as snakebite episodes and 566 were excluded (08 duplicates; 539 non-snakebite bites or stings; 19 entries with insufficient detail), leaving the 227 records abstracted and analysed. Data sources and data collection procedures Data were abstracted from outpatient and inpatient registers and, where available, individual patient files and clinical notes. Data abstraction was conducted at multiple service points, including adult and paediatric inpatient wards and, where applicable, Intensive Care Units (ICUs), to ensure comprehensive capture of cases across the spectrum of clinical severity. A semi-structured data abstraction tool was developed from relevant literature [ 9 , 20 ] and adapted to the Ugandan context. The tool captured (i) sociodemographic characteristics (age, sex, occupation, district, facility ownership); (ii) circumstances of the bite (year, quarter, anatomical site, snake type syndromes/manifestations where documented, time from bite to hospitalisation, where appropriate); (iii) pre-hospital first aid practices; (iv) diagnostic investigations performed, including the 20-minute whole-blood clotting test, INR/PT, complete blood count, renal function, and electrolytes; (vi) in-hospital treatment, including antivenom, antibiotics, corticosteroids, intravenous fluids, analgesics, tetanus toxoid, and supportive measures; and (vii) treatment outcomes (recovery, referral, death). The tool was pre-tested at 1 Public hospital: Kawempe Hospital with capacity to handle snakebites, to ensure clarity and consistency. Data collection was conducted by trained research assistants holding at least a Bachelor’s degree in nursing, clinical medicine, laboratory science, or environmental health, and with prior experience in health research. They underwent a three-day training covering study objectives, data abstraction procedures, ethical considerations, and confidentiality. A reference guide of common clinical terms relevant to snakebite envenomation was provided to minimise misclassification and ensure uniform interpretation. Ongoing supervision and periodic data quality checks were conducted to ensure completeness and accuracy. Data management and analysis Quantitative data were collected electronically using the KoboCollect mobile application (KoBoToolbox, Cambridge, MA, USA), with built-in skip patterns, range checks, and mandatory-field logic to enforce data quality at the point of entry. Data were exported in comma-separated values (CSV) format, cleaned, and imported into Stata version 14 (StataCorp, College Station, TX, USA) for analysis. During data management, records were screened for missing values and data entry errors, and where feasible missing information was verified against the original abstraction forms. The two continuous variables, age and time from bite to hospitalisation, were exami
## Related Clinical Research

- [Ransomware in US Health Care: Faster Exploitation and Smaller Breaches, 2016–2026](https://medichelpline.com/clinical-feed/medrxiv-6-the-shrinking-grace-period-and-the-downsizing-of-ransomware-victims.md)
- [Fentanyl dabbing with cannabis retail equipment: prevalence, practices, and clinical signals](https://medichelpline.com/clinical-feed/medrxiv-8-fentanyl-dabbing-with-cannabis-retail-equipment-an-ethnographic-and-drug.md)
- [MIF inhibitor ISO-1 reduces ischemia–reperfusion injury in rat DCD liver transplantation](https://medichelpline.com/clinical-feed/plos-one-14-mif-inhibitor-iso-1-attenuates-ischemia-reperfusion-injury-in-a-rat-model-of.md)
- [Admission interleukin-6 and short-term prognosis in hospitalized cirrhosis: etiology-dependent, ti](https://medichelpline.com/clinical-feed/plos-one-19-admission-interleukin-6-as-a-time-limited-etiology-dependent-prognostic-signal.md)
- [Renal Consequences of Inhaled Nitric Oxide in Critically Ill Patients](https://medichelpline.com/clinical-feed/pubmed-43061996.md) (DOI: 10.4103/mgr.MEDGASRES-D-26-00116)

## Navigation
- [← Back to General Feed](https://medichelpline.com/clinical-feed/general.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.